drugset / Trial / NCT02141477

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT02141477

NaSingle-groupOpen-labelTreatment

Summary

This clinical research study is made up of 2 phases. The goal of Phase 1 of the study is to test the safety of the combination of omacetaxine and decitabine and to find the best dose to give to future patients. The goal of Phase 2 of the study is to learn if this dose can help to control AML and/or MDS. The safety will then continue to be studied.

Timeline

Start
2015-05-06
Primary completion
2017-06-22
Completion
2017-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 Intravenous
Subject Omacetaxine Unknown 1.25 mg/m2 Subcutaneous

Indications